OS Therapies Advances Toward Global Approval for Osteosarcoma Treatment

OS Therapies Inc. (NYSE: OSTX) is making significant strides in the fight against osteosarcoma, as highlighted in a recent update from Stonegate Capital Partners. The company's lead candidate, OST-HER2, is advancing toward global approval for recurrent, fully resected, pulmonary metastatic osteosarcoma. A pivotal development is the European Medicines Agency (EMA) initiating a rolling review of the Conditional Marketing Authorization (CMA) dossier, while the EMA and Australia's Therapeutic Goods Administration (TGA) have aligned on 3-year overall survival (OS) as the approvable efficacy endpoint. This regulatory clarity shifts the focus from early proof-of-concept to execution, with management positioning seroconversion biomarker data as supportive surrogate efficacy evidence. The company has a dense 2026 catalyst calendar, including 2.5-year OS data in mid-2Q26, FDA/MHRA meetings in 2Q26, Phase 3 initiation in Australia in 3Q26, 3-year OS data in early 4Q26, and a potential EMA CMA decision in 4Q26.

Financing and optionality are key to bridging the regulatory window. OS Therapies raised $5.25 million and expects an additional $4.0 million in non-dilutive funding to support 2026 catalysts. A potential Priority Review Voucher (PRV) remains a meaningful approval-contingent valuation lever, with the latest public transaction at $205 million. The company's progress is underscored by key takeaways from the announcement: regulatory clarity as a core value inflection, survival data as the key catalyst stack, and financing/PRV optionality bridging the regulatory window. These developments could position OST-HER2 for a global approval pathway, potentially transforming treatment options for patients with this rare and aggressive cancer. For more details, click here to view the full announcement.

Stonegate Capital Partners, a leading capital markets advisory firm, provides investor relations, equity research, and institutional investor outreach services for public companies. Their affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services. This update from Stonegate underscores the growing momentum behind OS Therapies as it navigates the regulatory landscape, with multiple near-term milestones that could reshape the outlook for osteosarcoma treatment. The company's progress highlights the importance of innovative therapies in addressing unmet medical needs, and the potential for meaningful patient impact if approval is achieved.